The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.: IGF-1 is the major growth factor on myeloma

Archive ouverte

Sprynski, Anne Catherine | Hose, Dirk | Caillot, Laurent | Rème, Thierry | Shaughnessy Jr, John, D. | Barlogie, Bart | Seckinger, Anja | Moreaux, Jérôme | Hundemer, Michael | Jourdan, Michel | Meissner, Tobias | Jauch, Anna | Mahtouk, Karene | Kassambara, Alboukadel | Bertsch, Uta | Rossi, Jean-François | Goldschmidt, Hartmut | Klein, Bernard

Edité par CCSD ; American Society of Hematology -

International audience. A plethora of myeloma growth factors (MGF) has been identified, but their relative importance and cooperation has not been determined. We investigated 5 well-documented MGF (IL-6, IGF-1, HGF, HB-EGF, APRIL) in serum-free cultures of human myeloma cell lines (HMCLs). In all of 3 CD45(-) HMCLs, an autocrine IGF-1 loop promoted autonomous survival. To the contrary, all 5 CD45(+) HMCLs could not survive and required addition of either IL-6 (5/5), IGF-1 (4/5), HGF (1/5), HB-EGF (1/5) or APRIL (1/5). IGF-1 was the major MGF since its activity was abrogated by an IGF-1R inhibitor only, whereas IL-6, HGF or HB-EGF activity was inhibited by both IGF-1R- and receptor-specific inhibition. APRIL activity was inhibited by its specific inhibitor only. Of the investigated MGF and their receptors, only expressions of IGF-1R and IL-6R in myeloma cells (MMC) of patients delineate a group with adverse prognosis. This is mainly explained by a strong association of IGF-1R and IL-6R expression and t(4;14) translocation, but IGF-1R expression in MMC, without t(4;14) can also have a poor prognosis. Thus, IGF-1 targeted therapy - eventually in combination with anti-IL-6 therapy - could be promising in a subset of patients with MMC expressing IGF-1R.

Suggestions

Du même auteur

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Archive ouverte | Seckinger, Anja | CCSD

International audience. Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells. Given the freq...

Induction of angiogenesis by normal and malignant plasma cells.

Archive ouverte | Hose, Dirk | CCSD

International audience. Abundant bone marrow angiogenesis is present in almost all myeloma patients requiring therapy and correlated to treatment response and survival. We assessed the expression of 402 angiogenesis...

Inhibition of Aurora-kinases for tailored risk adapted treatment of multiple myeloma.

Archive ouverte | Hose, Dirk | CCSD

International audience. Genetic instability and cellular proliferation have been associated with Aurora-kinase expression in several cancer entities, including multiple myeloma. Therefore, the expression of Aurora-A...

Chargement des enrichissements...